Hologic (Nasdaq:HOLX) was an interesting undervalued health care play when the company was waiting on approval for its tomosynthesis product (a better type of breast imaging technology). With approval in hand, though, now the concerns move to customer adoption and low patient volumes throughout the testing business. Though still an attractive and high-quality franchise, the company is going to need to deliver more growth to get the Street excited about the name.

TUTORIAL: Economic Indicators To Know

A Fiscal Q2 That's Solid, but Not Spectacular
Hologic delivered a modest outperformance for the fiscal second quarter. Revenue rose about 5%, fueled by nearly 9% growth in the breast health business, as the company saw good pricing and some early adoption of the tomosynthesis product. Diagnostics was still weak (down more than 1%), though, as patient visit volume has not rebounded yet. Gyn/surgical and skeletal were both up above the company average, but these are smaller units.

The company delivered less good news on the margins. Gross margin slid a bit on product mix issues, and adjusted operating income fell 3%. All in all, though, the operating performance is not too troubling. The company's service costs were flat and administrative costs grew less than revenue. R&D and sales costs were the main drivers of the decline in operating profit, but neither are long-term worries - investors should expect higher sales to support the tomosynthesis rollout and higher R&D is the cost of staying in the game in med-tech.

Big Iron Getting Better
Hologic certainly has a lead on General Electric (NYSE:GE) and Siemens (NYSE:SI) in 3D breast tomosynthesis, but that does not make it an easy sell. These systems cost multiple hundreds of thousands of dollars and though the hospital capital budget environment is getting better, that is still a big outlay. Investors are probably right to think of this as a "when, not if" market, but the longer it takes for capital spending to rebound, the more of a competitive threat other companies will be.

Volume? Not So Much
When it comes to the diagnostics side, Hologic has issues similar to Qiagen (Nasdaq:QGEN), Gen-Probe (Nasdaq:GRPO), Abbott (NYSE:ABT) and Becton Dickinson (NYSE:BDX) - patient visit counts are weak and there is an arms race in the lab. Hologic's ThinPrep is good technology, but BDX will not just concede the market. Likewise, Hologic's Invader platform is solid, but Gen-Probe's Panther and BDX's MAX products are legitimate threats in their own right.

The Bottom Line
Right now, Hologic looks like it is basically fairly valued on the basis of mid-single digit revenue growth and some modest improvements in free cash flow margin. If the company can drive better tomosynthesis adoption and/or patient visits rebound strongly, there could be some upside in those numbers.

Longer term, this is a great focused business and it does not seem too outlandish to think that it will be an M&A target. The lack of growth in the business is probably an impediment today, but it could be an appealing option to whichever diagnostics companies find that they cannot compete effectively in the next-gen molecular diagnostics market.

In the meantime, this is another one of those well-run med-techs that is a decent hold but not so compelling for new money. (For related reading, also take a look at Investing In The Healthcare Sector.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  2. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  3. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  4. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  5. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  6. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  7. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  8. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  9. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  10. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center